wire - news in brief

« BACK

Life Sciences



Results 1 - 50 of 599.
1 2 3 4 5 ... 12 Next »

Medicine/Pharmacology - Life Sciences
23.06.2017
NEJM publishes full analysis of Rydapt (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)
Significant overall survival benefit observed for FLT3+ AML patients consistent across FLT3 mutation subgroups, including ITD and TKD Detailed data show Rydapt plus standard chemotherapy improved eve
Medicine/Pharmacology - Life Sciences
23.06.2017
Novartis Kisqali (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
Novartis Kisqali (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor CHMP opinio
Medicine/Pharmacology - Life Sciences
23.06.2017
Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data † Data evaluating 63 patients demonstrate relapse-free survival and probability of survival in a majority of patients at six months † Advances in CTL019 and ELIANA result from global CAR-T cell therapy collaboration with the University of Pennsylvania † CTL019 is manufactured us
Medicine/Pharmacology - Life Sciences
23.06.2017
Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers
Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers First in class BCL2-specific oral inhibitor represents a potential new way of treating different blood cancers Efficacy and tolerability confirmed in high-risk patients with relapsed or refractory chronic lymphocytic leukaemia, including those with 17p chromosomal de
Medicine/Pharmacology - Life Sciences
23.06.2017
FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Treatment can be administered in five to seven minutes, compared to 1.5 hour
Medicine/Pharmacology - Life Sciences
23.06.2017
Novartis combination targeted therapy Tafinlar + Mekinist receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)
Novartis combination targeted therapy Tafinlar + Mekinist receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC) Approval provides first targeted treatment in the U
Medicine/Pharmacology - Life Sciences
21.06.2017
Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance
AMG 334 (erenumab) is the first anti-CGRP monoclonal antibody developed for migraine prevention to receive EMA regulatory filing acceptance † Filing is supported by a comprehensive clinical program o
Medicine/Pharmacology - Life Sciences
19.06.2017
Sandoz receives approval in Europe for Rixathon‚? (biosimilar rituximab) to treat blood cancers and immunological diseases
European Commission approves Sandoz Rixathon ‚? to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics and enable budget-constrained healthcare systems to reallocate resources to other healthcare priorities.
Medicine/Pharmacology - Life Sciences
16.06.2017
Bacteria Free Themselves with Molecular ‘Speargun'
Bacteria Free Themselves with Molecular ‘Speargun’
Many bacteria are armed with nano-spearguns, which they use to combat unwelcome competitors or knockout host cells.
Life Sciences - Medicine/Pharmacology
15.06.2017
Gene Transfer Keeps Bacteria Fit
Gene Transfer Keeps Bacteria Fit
Researchers at the University of Basel‚?‘s Biozentrum have discovered that Bartonella bacteria exchange genes efficiently using a domesticated virus encoded in their genome.
Medicine/Pharmacology - Life Sciences
13.06.2017
Boost for Zurich biomedicine
Boost for Zurich biomedicine
The Helmut Horten Foundation has supported Zurich's medical hub for many years. Now, a new donation to ETH will enable the strengthening of the Zurich-Ticino ‘health axis'.
Life Sciences - Medicine/Pharmacology
12.06.2017
Fighting fire blight and detecting Salmonella
Fighting fire blight and detecting Salmonella
ETH researchers have created an effective weapon against the plant disease fire blight and a new method for detection of Salmonella. Both are based on particular viruses that attack only one species of bacteria. The plant disease fire blight, caused by the bacterium Erwinia amylovora , is dreaded by fruit growers.
Life Sciences - Medicine/Pharmacology
12.06.2017
Uncovering the biology of a painful and disfiguring pediatric disease
Uncovering the biology of a painful and disfiguring pediatric disease
EPFL scientists have identified the biological mechanism behind the painful, potentially lethal, disfiguring Hyaline Fibromatosis Syndrome.‚? Image caption:‚?Loss of ANTXR2 leads to the accumulation of extracellular material in mice uterus and sterility (Left). Collagen 6 removal in mice without ANTXR2 restore uterine structure and function (Right).
Life Sciences - Mathematics
12.06.2017
Hidden patterns of brain activity
In a collaboration led by EPFL‚?‘s Blue Brain, scientists discover patterns of brain activity ‚'' never before observed ‚?- with the help of mathematics, providing insight into how neurons collectively process information. Brains of healthy rats that are the same age share many features, such as similar numbers and types of neurons present in the six layers of the cortex.
Life Sciences - History/Archeology
09.06.2017
Ancient Bones Reveal Insights Into Swiss Wild Horse Population
Researchers from the University of Basel have, for the first time, studied how regional environmental changes influenced the populations of wild horses in Switzerland 25,000 years ago. Their results show: Contrary to the wild horses in the Eurasian steppe; the Swiss population grew considerably after the end of the last Ice Age.
Medicine/Pharmacology - Life Sciences
08.06.2017
Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
Data from the comprehensive clinical program show AMG 334 (erenumab) is safe and effective at preventing migraine in patients with 4 or more migraine days per month ‚?
Medicine/Pharmacology - Life Sciences
07.06.2017
Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
At interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff Best ORR was 59%, with 43% achi
Life Sciences - Physics/Materials Science
07.06.2017
More concepts, fewer facts
More concepts, fewer facts
ETH biology lecturers have tested secondary school leavers and students to determine their knowledge of biological concepts.
Life Sciences
06.06.2017
New findings could lead to improved in vitro testing
New findings could lead to improved in vitro testing
EPFL researchers propose a new approach of performing in vitro tests on nanoparticles that could enhance a correlation to in vivo results. This involves reproducing in the lab the dynamic and fluidic variations that these particles experience in the human body. Before new nanoparticles or other nanomedicines can be injected into the human body, a whole series of tests must be conducted in the laboratory, then in living cells, and in the end on humans.
Medicine/Pharmacology - Life Sciences
05.06.2017
Phase III study showed Roche‚? s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer
Phase III study showed Roche‚??s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer Second positive phase III head-to-head study to show Alecensa was superior to crizotinib in people with ALK-positive lung cancer Alecensa lowered the risk of tumour spread or growth in the brain or central nervous system Data will be simultaneously pub
Medicine/Pharmacology - Life Sciences
04.06.2017
Novartis landmark study of Tafinlar‚? + Mekinist‚? demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma
Novartis landmark study of Tafinlar‚? + Mekinist‚? demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma Study is longest follow-up to date o
Medicine/Pharmacology - Life Sciences
03.06.2017
Roche presents new data for TECENTRIQ‚? (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017
Roche presents new data for TECENTRIQ‚? (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017 Data evaluated TECENTRIQ in novel combinations across a broad range of tumours including lung, kidney and melanoma Promising Phase II combination data with TECENTRIQ plus Avastin (bevacizumab) in advanced kidney cancer First treatment-beyond-progression data from a Phase III study of cancer immunotherapy in a
Medicine/Pharmacology - Life Sciences
02.06.2017
Novartis presents updated data that reinforce the efficacy and safety of Kisqali (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
Novartis presents updated data that reinforce the efficacy and safety of Kisqali (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer At a subsequent
Medicine/Pharmacology - Life Sciences
02.06.2017
A new approach to combatting anxiety states, pain and inflammation
A new approach to combatting anxiety states, pain and inflammation
Media releases, information for representatives of the media Media Relations (E) Endogenous cannabinoids (endocannabinoids) play an important role in the brain and immune system. Bern researchers from the National Centre of Competence in Research (NCCR) "TransCure" have now found a new way to influence the endocannabinoid system.
Life Sciences
01.06.2017
New research tools
New research tools
At the age of 29, biotechnologist Randall Platt has already achieved a lot: more than 1,000 research laboratories around the world use a method that he developed.
Medicine/Pharmacology - Life Sciences
31.05.2017
Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency
Sandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in all indications of their respective reference medicines, Humira * and Remicade ** Comprehensive data pac
Medicine/Pharmacology - Life Sciences
31.05.2017
Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients
Eight of nine evaluable patients tested had no signs of CLL in their bone marrow at three months. CTL119 is a humanized CD19-directed CAR-T cell therapy being developed in collaboration with the University of Pennsylvania Novartis is committed to advancing a portfolio of next-generation CAR-T cell therapies - Novartis announced findings from a pilot study (NCT02640209) of CTL119 in combination with ibrutinib* in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who had been taking ibrutinib for at least six months and who were not in complete remission.
Medicine/Pharmacology - Life Sciences
30.05.2017
Resistant Cancer Cells: 3D Structure of a Drug Transporter Decoded
Resistant Cancer Cells: 3D Structure of a Drug Transporter Decoded
Drug resistance is not only a major problem in fighting infectious diseases. Also in the treatment of cancer it can jeopardize the success of chemotherapy.
Medicine/Pharmacology - Life Sciences
26.05.2017
Designer Viruses Stimulate the Immune System to Fight Cancer
Swiss scientists have created artificial viruses that can be used to target cancer. These designer viruses alert the immune system and cause it to send killer cells to help fight the tumor. The results, published Communications, provide a basis for innovative cancer treatments. Most cancer cells only provoke a limited reaction from the immune system – the body's defense mechanism – and can thus grow without appreciable resistance.
Medicine/Pharmacology - Life Sciences
26.05.2017
Novartis receives FDA approval for expanded use of Zykadia in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)
In ALK-positive metastatic NSCLC patients, Zykadia median progression-free survival (PFS) was 16.6 months, compared to 8.1 months with chemotherapy † The overall intracranial response r
Life Sciences - Medicine/Pharmacology
23.05.2017
Revealing how neurons communicate
Revealing how neurons communicate
The ETH spinoff MaxWell Biosystems AG develops microelectrode platforms for electrophysiological tests on nerve cells, opening up new possibilities for pharmaceutical research. Now, the company received CHF 130,000 in starting capital from the Venture Kick initiative MaxWell Biosystems AG's head office is hidden away in a Basel laboratory building previously used by Syngenta, just a stone's throw from ETH Zurich's Department of Biosystems Science and Engineering (D-BSSE).
Medicine/Pharmacology - Life Sciences
23.05.2017
Discovery of a Key Regulatory Gene in Cardiac Valve Formation
Researchers from the University of Basel in Switzerland have identified a key regulator gene for the formation of cardiac valves - a process crucial to normal embryonic heart development. These results are published in the journal Cell Reports today. The heart is the first functional organ that develops in vertebrate embryos.
Medicine/Pharmacology - Life Sciences
23.05.2017
FDA approves Roche’s Actemra/RoActemra (tocilizumab) for giant cell arteritis
FDA approves Roche's Actemra/RoActemra (tocilizumab) for giant cell arteritis Actemra/RoActemra is the first FDA-approved treatment for adults with giant cell arteritis (GCA) FDA previously granted Priority Review and Breakthrough Therapy Designation for Actemra/RoActemra in GCA Sixth FDA approval for Actemra/RoActemra since its US launch in 2010 Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra /RoActemra (tocilizumab) ) subcutaneous injection for the treatment of GCA, a chronic and severe autoimmune condition.
Life Sciences
22.05.2017
Digital birdhouses make studying owls easier
Digital birdhouses make studying owls easier
EPFL students have developed a system that can detect when barn owls fly into and out of their nests, without disturbing the birds.
Medicine/Pharmacology - Life Sciences
19.05.2017
Novartis receives positive CHMP opinion for first-line use of Zykadia in ALK-positive advanced non-small cell lung cancer (NSCLC)
Phase III trial, first-line treatment with Zykadia resulted in improved progression-free survival (PFS) over SOC chemotherapy with maintenance, including in patients with brain metastases Zykadia is
Medicine/Pharmacology - Life Sciences
18.05.2017
Novartis data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer care
Updated analyses from the Kisqali pivotal Phase III MONALEESA-2 trial in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer to be presente
Life Sciences - Architecture
18.05.2017
15 new professors
15 new professors
At its meeting of 17 May 2017, the ETH Board appointed 15 new professors upon application of ETH Zurich President Lino Guzzella.
Life Sciences - Medicine/Pharmacology
10.05.2017
Two major projects drive genetics research forward at Campus Biotech
Two major projects drive genetics research forward at Campus Biotech
Good news for the fields of genetic research and gene therapy: two major projects based at Campus Biotech, EPFL's outpost in Geneva, were announced simultaneously today.
Life Sciences - Environment/Sustainable Development
08.05.2017
What silver fir aDNA can tell us about Neolithic forests
What silver fir aDNA can tell us about Neolithic forests
Media releases, information for representatives of the media Media Relations (E) A new technique makes it possible to cost-effectively analyse genetic material from fossil plant and animal remains. Researchers from the Swiss Federal Institute for Forest, Snow and Landscape Research WSL and the universities of Lausanne and Bern have used this technique to examine the DNA of silver fir needles found in lake sediment in Ticino.
Medicine/Pharmacology - Life Sciences
04.05.2017
Comprehensive Atlas of Immune Cells in Renal Cancer
Comprehensive Atlas of Immune Cells in Renal Cancer
Renal cell carcinoma is one of the most frequent and deadly urogenital cancers. Even if the tumors are treated, they ultimately end in metastasis in about half of the patients. 90 percent of these patients die within five years. Thanks to new kinds of immunotherapies, the outlook of this patient group has improved, but the treatment only works for a minority of patients.
Life Sciences - Physics/Materials Science
04.05.2017
A magic hood for artificial heart pumps
A magic hood for artificial heart pumps
Ten million people in Europe alone suffer from cardiac insufficiency, or a weak heart. One day, many of them may require a heart transplant.
Medicine/Pharmacology - Life Sciences
28.04.2017
Novartis receives FDA approval for Rydapt in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM)
Novartis receives FDA approval for Rydapt in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM) Approval in newly diagnosed FLT3-mutated AML repre
Life Sciences - Medicine/Pharmacology
26.04.2017
Link Discovered between Immune System, Brain Structure and Memory
Link Discovered between Immune System, Brain Structure and Memory
In two independent studies, scientists at the University of Basel have demonstrated that both the structure of the brain and several memory functions are linked to immune system genes. The scientific journals Nature Communications and Nature Human Behaviour have published the results of the research.
Medicine/Pharmacology - Life Sciences
24.04.2017
Novartis real-world data at AAN confirms benefit of Gilenya on four key measures of disease activity in relapsing MS
Over 16 months, more than 75% of patients on Gilenya had either no relapses, no new or enlarged MRI lesions or no disability progression; around 58% showed brain shrinkage levels broadly within the range expected for people without MS † Approximately 60% of patients achieved NEDA-3 (no relapses, no MRI lesions and no disability progression combined) and 38% achieved NEDA-4 (NEDA-3 plus no brain shrinkage), further supporting findings from clinic
Medicine/Pharmacology - Life Sciences
24.04.2017
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada Novartis and Amgen to co-commercialize AMG 334
Medicine/Pharmacology - Life Sciences
21.04.2017
Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*
Sandoz receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases.
Medicine/Pharmacology - Life Sciences
19.04.2017
Action Required: Invasive Fungus Is Killing European Salamanders
The situation is alarming: The invasive Asian fungus has recently led to mass mortality of fire salamanders in the Netherlands, Belgium and Germany.
Medicine/Pharmacology - Life Sciences
19.04.2017
Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS? (ocrelizumab) in two types of multiple sclerosis
Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS? (ocrelizumab) in two types of multiple sclerosis Data presentations will include platform sessions and
Medicine/Pharmacology - Life Sciences
18.04.2017
FDA grants Roche’s TECENTRIQ (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer
FDA grants Roche's TECENTRIQ (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer First and only cancer immunotherapy approved in advanced bladder
1 2 3 4 5 ... 12 Next »